Study Title
Interfant21: International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
Protocol ID
Interfant21
Condition/s
B- precursor acute lymphoblastic leukemia (ALL)
B- cell mixed phenotype acute leukemia (MPAL)
B- cell mixed phenotype acute leukemia (MPAL)
Diagnosis Stage
Newly diagnosed
Location
NSW, QLD, VIC, WA, SA
Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators
Princess Maxima Center for Pediatric Oncology
Links
Trial Status
Open
Sites
Perth Children's Hospital
Monash Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Women's and Children's Hospital
Monash Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Women's and Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 1 Year
International registry ID's
NCT05327894
| Study Title | Interfant21: International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia |
|---|---|
| Protocol ID | Interfant21 |
| Disease (Sub Disease) | B- precursor acute lymphoblastic leukemia (ALL) B- cell mixed phenotype acute leukemia (MPAL) |
| Diagnosis Stage | Newly diagnosed |
| Location | NSW / QLD / VIC / WA / SA |
| Sponsor | Australian & New Zealand Children's Haematology/Oncology Group |
| Collaborators | Princess Maxima Center for Pediatric Oncology |
| Links | https://clinicaltrials.gov/study/NCT05327894 |
| Trial Status | Open |
| Trial Open Date | 30/04/2024 |
| Sites | Perth Children's Hospital/ Monash Children's Hospital/ Queensland Children's Hospital/ The Children's Hospital at Westmead/ Women's and Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 1 Year |
| International registry ID's | NCT05327894 |